Profile data is unavailable for this security.
About the company
Astellas Pharma Inc is a Japan-based company mainly engaged in the research, development, manufacture and sales of pharmaceutical products. The Company mainly operates Pharmaceutical Products business segment. The main products include XTANDI, BETANIS, MIRABETRIC, BETMIGA and new products ZOSPATA, EVERENZO and ENHOLTUMAB VEDOTIN, among others.
- Revenue in JPY (TTM)2.06tn
- Net income in JPY322.91bn
- Incorporated1939
- Employees13.64k
- LocationAstellas Pharma Inc2-5-1, Nihombashihon-choCHUO-KU 103-8411JapanJPN
- Phone+81 332443000
- Websitehttps://www.astellas.com/jp/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sumitomo Pharma Co Ltd | 453.40bn | 110.09bn | 983.01bn | 3.83k | 8.92 | 3.40 | 7.46 | 2.17 | 277.11 | 277.11 | 1,141.22 | 727.28 | 0.5438 | 1.95 | 3.99 | 118,318,100.00 | 13.20 | -5.49 | 23.02 | -8.49 | 59.24 | 67.88 | 24.28 | -13.24 | 1.01 | 4.17 | 0.4726 | -- | 26.79 | -3.75 | 107.50 | -10.32 | -0.4856 | -- |
| Ono Pharmaceutical Co Ltd | 509.35bn | 62.40bn | 1.26tn | 4.29k | 19.11 | 1.42 | 12.73 | 2.48 | 132.76 | 132.76 | 1,084.01 | 1,786.88 | 0.4702 | 2.14 | 3.38 | 118,811,500.00 | 5.77 | 10.78 | 6.61 | 12.37 | 69.79 | 73.23 | 12.27 | 21.23 | 2.56 | 125.26 | 0.1283 | 36.33 | -3.14 | 10.73 | -60.89 | -3.47 | -18.66 | 12.20 |
| Kyowa Kirin Co Ltd | 496.83bn | 67.04bn | 1.41tn | 5.67k | 21.01 | 1.58 | 15.18 | 2.85 | 128.07 | 128.07 | 949.13 | 1,706.50 | 0.4568 | 1.82 | 2.99 | -- | 6.16 | 6.40 | 7.33 | 7.37 | 74.25 | 74.99 | 13.49 | 14.37 | 2.35 | -- | -- | 46.19 | 0.2559 | 9.31 | 11.98 | 7.35 | 19.80 | 7.10 |
| Eisai Co Ltd | 808.19bn | 42.76bn | 1.48tn | 13.51k | 33.40 | 1.61 | 17.65 | 1.83 | 151.67 | 151.67 | 2,866.61 | 3,153.46 | 0.5537 | 0.7996 | 3.33 | 59,839,040.00 | 3.04 | 3.81 | 4.22 | 5.14 | 77.75 | 77.47 | 5.48 | 6.44 | 1.54 | -- | 0.2015 | 98.01 | 6.42 | 2.56 | 9.49 | -17.54 | -14.48 | 0.00 |
| Shionogi & Co Ltd | 465.35bn | 194.86bn | 3.15tn | 4.96k | 15.45 | 1.99 | 14.58 | 6.76 | 228.94 | 228.94 | 546.70 | 1,779.33 | 0.2869 | 0.8648 | 2.76 | 93,915,640.00 | 11.98 | 12.17 | 13.13 | 13.74 | 84.50 | 84.91 | 41.78 | 38.30 | 5.21 | -- | 0.0148 | 27.87 | 0.7325 | 5.62 | 5.19 | 6.88 | 34.66 | 12.30 |
| Astellas Pharma Inc | 2.06tn | 322.91bn | 4.54tn | 13.64k | 13.98 | 2.55 | 8.83 | 2.20 | 179.57 | 179.57 | 1,145.43 | 984.21 | 0.5841 | 1.27 | 2.90 | 151,038,200.00 | 9.15 | 3.05 | 14.11 | 4.45 | 81.00 | 81.15 | 15.67 | 5.42 | 0.839 | 41.32 | 0.2913 | 131.42 | 19.25 | 8.01 | 197.72 | -23.64 | -5.94 | 13.09 |
| Daiichi Sankyo Co Ltd | 2.05tn | 304.60bn | 5.56tn | 19.77k | 17.95 | 3.18 | 14.69 | 2.71 | 163.62 | 163.62 | 1,103.05 | 924.09 | 0.5649 | 0.8183 | 3.11 | 103,827,400.00 | 8.38 | 5.72 | 10.55 | 7.11 | 77.54 | 72.15 | 14.84 | 11.03 | 1.85 | -- | 0.1495 | 49.57 | 17.77 | 13.95 | 44.47 | 17.77 | 29.01 | 20.79 |
| Otsuka Holdings Co Ltd | 2.42tn | 449.11bn | 5.75tn | 35.34k | 12.56 | 1.96 | 10.17 | 2.38 | 842.65 | 842.65 | 4,540.85 | 5,413.66 | 0.64 | 2.11 | 4.86 | 68,439,860.00 | 12.01 | 5.91 | 15.12 | 7.27 | 71.72 | 69.18 | 18.76 | 9.89 | 1.65 | -- | 0.0695 | 32.93 | 15.42 | 10.78 | 182.13 | 21.96 | 15.32 | 3.71 |
| Takeda Pharmaceutical Co Ltd | 4.46tn | 112.93bn | 8.93tn | 47.46k | 77.69 | 1.16 | 10.38 | 2.00 | 72.26 | 72.26 | 2,834.46 | 4,838.54 | 0.2926 | 1.17 | 6.17 | 94,080,250.00 | 0.7418 | 1.71 | 0.8772 | 2.04 | 65.33 | 67.66 | 2.54 | 5.99 | 0.6548 | 3.49 | 0.3884 | 123.75 | 7.45 | 6.84 | -25.08 | 19.53 | 9.82 | 1.72 |
| Chugai Pharmaceutical Co Ltd | 1.26tn | 434.01bn | 15.58tn | 7.78k | 35.19 | 7.54 | -- | 12.39 | 263.73 | 263.73 | 764.40 | 1,230.91 | 0.5379 | 1.41 | 3.59 | -- | 18.56 | 19.40 | 21.83 | 23.54 | 71.09 | 66.75 | 34.50 | 31.46 | 3.56 | 583.66 | -- | 40.95 | 7.46 | 9.84 | 12.06 | 15.11 | 12.69 | 17.27 |
Data as of Feb 13 2026. Currency figures normalised to Astellas Pharma Inc's reporting currency: Japanese Yen JPY
30.47%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Nomura Asset Management Co., Ltd.as of 08 Jan 2026 | 118.73m | 6.56% |
| BlackRock Fund Advisorsas of 15 Jan 2026 | 71.82m | 3.97% |
| The Vanguard Group, Inc.as of 07 Jan 2026 | 66.49m | 3.67% |
| Sumitomo Mitsui Trust Asset Management Co., Ltd.as of 15 Sep 2025 | 58.38m | 3.23% |
| Amova Asset Management Co., Ltd.as of 15 Sep 2025 | 57.14m | 3.16% |
| Daiwa Asset Management Co. Ltd.as of 30 Dec 2025 | 49.31m | 2.73% |
| BlackRock Japan Co. Ltd.as of 15 Jan 2026 | 40.50m | 2.24% |
| Mitsubishi UFJ Asset Management Co., Ltd.as of 08 Jan 2026 | 33.84m | 1.87% |
| Norges Bank Investment Managementas of 30 Jun 2025 | 28.47m | 1.57% |
| Geode Capital Management LLCas of 05 Feb 2026 | 26.67m | 1.47% |
More ▼
Data from 30 Jun 2025 - 05 Feb 2026Source: FactSet Research Systems Inc.
